Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
MEFOXIN |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cephalosporin. |
| Generic Name |
|
Cefoxitin sodium 1g, 2g; for IV inj; sodium content 2.3mEq/g. |
| Indications |
|
Susceptible bacterial septicemia, lower respiratory or urinary tract, skin and skin structure, bone and joint, gynecologic, intraabdominal infections. Surgical prophylaxis. |
| Children |
|
<3months: not recommended. ≥3months: 80-160mg/kg per day in 4-6 equal divided doses; max 12g/day. Prophylaxis: see literature. |
| Adults |
|
Usually 1–2g every 6–8 hrs. Uncomplicated: 1g every 6–8 hrs. Moderately severe to severe: 1g every 4 hrs or 2g every 6–8 hrs. Max 2g every 4 hrs or 3g every 6 hrs. Prophylaxis: see literature. |
| Precautions |
|
Penicillin or other allergy. Renal impairment (CrCl <50mL/min), reduce dose: see literature. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Aminoglycosides may potentiate nephrotoxicity. Potentiated by probenecid. May cause false (+) Clinitest. May interfere with creatinine tests. |
| Adverse Reactions |
|
Local reactions, rash, pruritus, drug fever, GI upset, anaphylaxis, blood dyscrasias, elevated liver enzymes. |
| How Supplied |
|
Vials (1g, 2g)—25 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
